QoL (Quality of Life ) in High-Risk MDS & AML: A recorded zoom session with specialist consultants & MDS UK patients26 Jan. 2023
On December 15th 2022, Dr Pramila Krishnamurthy, and her colleagues Dr Beth Payne, and Dr Ian Thomas, led this valuable session introducing their research project on QoL (Quality of Life ) in High-Risk MDS & AML to a group of MDS UK patients. The presentation was followed by Q&As.
Below is a recording of that session. It was chaired by Sophie Wintrich, CEO and Trustee of MDS UK Patient Support Group. The recording is approximately 1hr 10m. For more on the specialist speakers, see their profiles below.
Dr Beth Payne is haematology consultant at UCLH and specialises in the treatment of MDS and bone marrow failure. She undertook her PhD at the Dana-Farber Cancer Institute, Harvard Medical School in Boston, USA studying molecular aspects of MDS and AML and ribosomal protein mediated disorders. Dr Payne was awarded an Advanced Clinician Scientist Fellowship by Cancer Research UK.
Dr Ian Thomas is a Research Fellow within the Blood Cancer group, at the UKCRC Registered Centre for Trials Research at Cardiff University. He has worked on international clinical trials, predominantly in acute myeloid leukaemia, since 2007.